Literature DB >> 30867104

Ovarian Cancer: An Integrated Review.

Christine Stewart1, Christine Ralyea2, Suzy Lockwood3.   

Abstract

OBJECTIVE: To provide an overview of the risk factors, modifiable and non-modifiable, for ovarian cancer as well as prevention, diagnostic, treatment, and long-term survivorship concerns. This article will also examine current and future clinical trials surrounding ovarian cancer. DATA SOURCES: A review of articles dated 2006-2018 from CINAHL, UpToDate, and National Comprehensive Cancer Network guidelines.
CONCLUSION: There is no screening test for ovarian cancer and with diagnosis often in the late stages, recurrence is high in this population. Early identification can range from knowing the vague symptoms associated with the cancer to prophylactic surgical removal of at-risk tissue. Standard treatment for ovarian cancer is surgery followed by combination chemotherapy. Although advances are being made, ovarian cancer remains the most fatal female gynecologic cancer. IMPLICATIONS FOR NURSING PRACTICE: Becoming familiar with and educating women about risk factors and the elusive symptoms of ovarian cancer can increase patient autonomy and advocacy, as well as potentially improve patient outcomes for those affected by ovarian cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA; gynecologic; oncology; ovarian cancer; prevention; risk factors

Year:  2019        PMID: 30867104     DOI: 10.1016/j.soncn.2019.02.001

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  151 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  Proteomics advances for precision therapy in ovarian cancer.

Authors:  Marilyne Labrie; Nicholas D Kendsersky; Hongli Ma; Lydia Campbell; Jennifer Eng; Koei Chin; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2019-09-13       Impact factor: 3.940

3.  Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.

Authors:  Hye Jin Lee; Emily B Ehlerding; Dawei Jiang; Todd E Barnhart; Tianye Cao; Weijun Wei; Carolina A Ferreira; Peng Huang; Jonathan W Engle; Weibo Cai
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

4.  The roles of HOXB8 through activating Wnt/β-catenin and STAT3 signaling pathways in the growth, migration and invasion of ovarian cancer cells.

Authors:  Lidan Liu; Lifei Wang; Xiujuan Li
Journal:  Cytotechnology       Date:  2022-01-03       Impact factor: 2.058

5.  Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis.

Authors:  Sarama Saha; Seema Parte; Partha Roy; Sham S Kakar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.

Authors:  Sheril June Ankasha; Mohamad Nasir Shafiee; Norhazlina Abdul Wahab; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

7.  The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p.

Authors:  Liping Wang; Chenchen Ren; Yajuan Xu; Li Yang; Yannan Chen; Yuanhang Zhu
Journal:  J Ovarian Res       Date:  2021-06-11       Impact factor: 4.234

8.  Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro.

Authors:  Yi Wu; Zhong Zhang; Zuqiang Kou
Journal:  Drug Des Devel Ther       Date:  2021-07-01       Impact factor: 4.162

9.  Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients.

Authors:  Jun Li; Sile Han; Cuiyun Zhang; Yanlin Luo; Li Wang; Ping Wang; Yi Wang; Qingxin Xia; Xiaoyan Wang; Bing Wei; Jie Ma; Hongle Li; Yongjun Guo
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

10.  Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.

Authors:  Min Chen; Juan Su; Chunmei Feng; Ying Liu; Li Zhao; Yongjie Tian
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.